Fanciullacci M, Alessandri M, Pietrini U, Briccolani-Bandini E, Beatrice S
Institute of Internal Medicine and Therapeutics IV, Headache Centre, Florence University, Firenze, Italy.
Clin Pharmacol Ther. 1992 Mar;51(3):302-7. doi: 10.1038/clpt.1992.26.
The mydriatic action of sympathomimetic eyedrops after a therapeutic dose of ergotamine was measured in migraine patients with and without histories of long-term ergotamine abuse. Mydriasis induced by the postsynaptic alpha 1-agonist phenylephrine was similar in both groups of patients tested, whereas pupillary dilation caused by the release of noradrenaline tyramine was markedly greater in patients with histories of ergotamine abuse. The enhanced response to tyramine disappeared after drug withdrawal. These findings indicate that continuous ergotamine medication causes a reversible alterations in iris sympathetic transmission. This manifestation may reflect a central inhibition of pupillary sympathetic activity.
在有或没有长期麦角胺滥用史的偏头痛患者中，测定了治疗剂量麦角胺后拟交感神经眼药水的散瞳作用。在两组受试患者中，由突触后α1-激动剂去氧肾上腺素诱导的瞳孔散大相似，而在有麦角胺滥用史的患者中，由去甲肾上腺素酪胺释放引起的瞳孔扩张明显更大。停药后对酪胺的增强反应消失。这些发现表明，持续使用麦角胺会导致虹膜交感神经传递发生可逆性改变。这种表现可能反映了瞳孔交感神经活动的中枢抑制。
